MedTrace Logo

Subarachnoid Hemorrhage Recovery And Galantamine

NCT02872857 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-10-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the effects of the study drug--Galantamine-on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.

Conditions

  • Subarachnoid Hemorrhage

Interventions

DRUG

Placebo

Placebo will match drug capsules.

DRUG

8mg galantamine twice daily

Drug will be administered within 36 hours of hospitalization and continued for 90 days.

DRUG

12mg galantamine twice daily

Drug will be administered within 36 hours of hospitalization and continued for 90 days.

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Huimahn Choi, MD, MS · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-07-20
Completion
2019-07-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02872857 on ClinicalTrials.gov